Anterior Resection Syndrome Following Sphincter-preserving Surgery

Sponsor
Queen Mary University of London (Other)
Overall Status
Completed
CT.gov ID
NCT02190656
Collaborator
The Royal College of Surgeons of England (Other)
1,197
1
16
74.7

Study Details

Study Description

Brief Summary

Bowel cancer is the third most common cancer in the UK in both males and females. The rectum is the most commonly affected part of the bowel. Improvements in surgery have meant that many patients with rectal cancer can now undergo surgery that removes the rectum and avoids a permanent stoma. The operation that most patients have is an anterior resection of the rectum.

Unfortunately this surgery frequently leads to a change in bowel function, with patients suffering from incontinence, urgency and unpredictability a problem known as anterior resection syndrome. These problems are believed to be fairly common following surgery but follow up appointments have traditionally concentrated on ensuring that the cancer has not returned and have not reviewed functional outcomes in enough detail. Because of this we are unsure exactly how common the problems described are.

The proposed study will allow us to determine how many patients have ongoing symptoms following their surgery for rectal cancer. It will also allow us to use a newly developed scoring system the Low Anterior Resection Syndrome (LARS) score for the first time in a UK population, to ensure that it can accurately be used in the future to measure the problem and aid development of new therapies. An appreciation of the impact of symptoms on postoperative quality of life will encourage routine assessment of functional outcomes in clinical practice, allowing identification of patients who may benefit from treatment.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    One of the main aims when carrying out surgery for rectal cancer is to avoid patients ending up with a permanent stoma. The current standard operation for resection of the rectum is an anterior resection. A large proportion of the patients undergoing this procedure develop anterior resection syndrome, with significant alteration of their bowel habit, including urgency, incontinence and unpredictability. Many definitions for this problem have been used and until recently there was no specifically designed tool for measuring it. There has never been a large scale study in the UK to tell us how common the problem is. A meta-analysis combining results from small studies show marked variation in the frequency of symptoms ranging from 285%, mainly because of the different methods of assessment used in the studies.

    The LARS score was recently developed by a research group in Denmark. Their results show that 45.9% of patients had major LARS at 12 months following surgery. This is nearly half of all patients in their sample and clearly represents an important problem.

    Anterior resection syndrome is known to have a negative effect on quality of life. It is a multifactorial condition and is increased in patients have chemotherapy and radiotherapy. There are treatments available and also in development which may help patients. However in clinical practice, patients are not routinely asked about their functional outcome and the effect that these symptoms can have on patients' lives is often not discussed. The urgent need for further research into the longterm functional effects of treatments for cancer has been acknowledged by the National Institute for Health and Care Excellence (NICE) and the National Cancer Survivorship Initiative.

    Determining baseline prevalence in the UK and validating the LARS score will allow accurate preoperative counselling of patients about functional outcomes following surgery for rectal cancer. It will facilitate comparison between populations, further helping to determine risk factors and aiding in development of therapeutic interventions. An appreciation of the impact of anterior resection syndrome on postoperative quality of life will encourage routine assessment of functional outcomes in clinical practice, allowing identification of patients who may benefit from treatment.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    1197 participants
    Time Perspective:
    Cross-Sectional
    Official Title:
    Anterior Resection Syndrome Following Sphincter-preserving Surgery
    Study Start Date :
    May 1, 2014
    Actual Primary Completion Date :
    Jun 1, 2015
    Actual Study Completion Date :
    Sep 1, 2015

    Arms and Interventions

    Arm Intervention/Treatment
    Anterior resection

    Patients having had an anterior resection for rectal cancer who are more than 12 months post surgery

    Outcome Measures

    Primary Outcome Measures

    1. Number of participants with no LARS; minor LARS and major LARS [At the time of questionnaire completion]

      This will allow us to determine the prevalence of Low Anterior Resection Syndrome

    Secondary Outcome Measures

    1. Correlation between LARS score and EORTC QLQ-C30 questionnaire score [At the time of questionnaire completion]

      The association between the LARS score and The European Organization for Research and Treatment of Cancer (EORTC) generic quality of life questionnaire QLQC30 will be used to establish validity of the LARS score. Ability of the score to differ between patient groups known to differ in postoperative function (for example, those who have had radiotherapy and those who have not) will also be used to assess validity.

    Other Outcome Measures

    1. LARS score in different age groups [At time of questionnaire completion]

    2. LARS score in participants who have had laparoscopic surgery and participants who have had open surgery [At time of questionnaire completion]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients having had an anterior resection for rectal cancer who are more than 12 months post surgery

    • Patients who are more than 12 months post reversal of any defunctioning stoma

    • Aged over 18 years

    Exclusion Criteria:
    • Any inclusion criteria not met

    • Presence of a stoma

    • Local recurrence of cancer

    • Current adjuvant therapy

    • Further rectal surgery after the initial operation

    • Insufficient written English to participate

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Queen Mary University of London London United Kingdom E1 2AT

    Sponsors and Collaborators

    • Queen Mary University of London
    • The Royal College of Surgeons of England

    Investigators

    • Study Chair: Mohamed Thaha, PhD FRCS, Queen Mary University of London

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Queen Mary University of London
    ClinicalTrials.gov Identifier:
    NCT02190656
    Other Study ID Numbers:
    • 009515
    First Posted:
    Jul 15, 2014
    Last Update Posted:
    Apr 5, 2016
    Last Verified:
    Apr 1, 2016
    Keywords provided by Queen Mary University of London
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 5, 2016